? ADMINISTRATIVE CORE The Administrative Core at Fox Chase Cancer Center (FCCC) is organized to provide all of the support functions for senior leadership, center membership and operations. The Core plays a major role in facilitating the creation of FCCC's vision and goals, managing Evaluation and Planning and the activities of external and internal committees, creating and implementing the FCCC Strategic Plan, monitoring progress, overseeing the operations of Shared Resources and ensuring that researchers have the resources that they require. Senior administrative staff members meet with Fisher and other FCCC leaders weekly to review all aspects of Center operations. Administrative Core staff are responsible for oversight and management of the Center's 12 Shared Resources, the research budget; facilitating purchasing; management of sponsored programs including pre- and post-award; human resource management; Developmental Funds operations including organizing pilot grant reviews; tracking and review of Cancer Center membership; monitoring member grants, publications, clinical trials and other CCSG metrics; management of external and internal advisory committee meetings; oversight of space allocation and space planning; and logistics of faculty recruitment. Inasmuch as FCCC is a self-contained organization, the Administrative Core works in partnership with the institutional offices of Communication, Marketing, and Institutional Advancement on all aspects of the Center that involve public relations. The Core also provides primary support for the Office of Community Outreach, and financial oversight and management for FCCC's education and training components. For faculty on the FCCC-main campus, the Administrative Core manages all operational aspects of their laboratories and resources. For Cancer Center members located on the Temple campuses, the Administrative Core supports their counterparts within the university. All cancer related research review and human subjects review is managed by FCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-55
Application #
9996555
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-07-01
Project End
2021-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
55
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Fareed, Muhammad M; Eldib, Ahmed; Weiss, Stephanie E et al. (2018) A treatment planning comparison between a novel rotating gamma system and robotic linear accelerator based intracranial stereotactic radiosurgery/radiotherapy. Phys Med Biol 63:035029
Bleicher, Richard J (2018) Timing and Delays in Breast Cancer Evaluation and Treatment. Ann Surg Oncol 25:2829-2838
Bai, Tian; Chanda, Ashis Kumar; Egleston, Brian L et al. (2018) EHR phenotyping via jointly embedding medical concepts and words into a unified vector space. BMC Med Inform Decis Mak 18:123
Mehrazin, Reza; Dulaimi, Essel; Uzzo, Robert G et al. (2018) The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Ther Adv Urol 10:3-10
Tang, Baiqing; Lee, Hyung-Ok; An, Serim S et al. (2018) Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine. Cancer Res 78:4386-4395
Fang, Carolyn Y; Tseng, Marilyn (2018) Ethnic density and cancer: A review of the evidence. Cancer 124:1877-1903
Malik, R; Luong, T; Cao, X et al. (2018) Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol :
Giri, Veda N; Obeid, Elias; Hegarty, Sarah E et al. (2018) Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 78:879-888
Anari, Fern; O'Neill, John; Choi, Woonyoung et al. (2018) Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol 1:54-60
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1280 publications